收稿日期: 2023-04-06
录用日期: 2023-05-22
网络出版日期: 2023-10-28
基金资助
上海市自然科学基金(23ZR1436100)
Research on the role of SOX9 in regulating metabolic reprogramming in diffuse large B cell lymphoma
Received date: 2023-04-06
Accepted date: 2023-05-22
Online published: 2023-10-28
Supported by
Natural Science Foundation of Shanghai(23ZR1436100)
目的·探索弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中差异表达的性别决定区Y框转录因子9(SRY-box transcription factor 9,SOX9)基因所起到的作用,尤其是在生发中心B细胞(germinal center B-cell,GCB)来源亚型中对代谢重编程的调控作用。方法·选取NCICCR-DLBCL数据库中的481例DLBCL患者的临床信息和基因表达谱数据,使用R语言4.1.3版本进行数据分析与可视化,并基于RNA-seq测序表达量的细胞组织来源亚型(cell of origin subtype,COO)分类算法进行分类;使用ABC/GCB特征注释基因集,通过基因集富集分析(gene set enrichment analysis,GSEA)对分类进行验证。以SOX9的表达量高低将ABC和GCB亚组分别二分类。使用DEseq2包进行差异分析。使用KEGG(Kyoto Encyclopedia of Genes and Genomes)与Hallmark注释集分析SOX9与DLBCL的代谢的关系。采用Kaplan-Meier方法绘制生存曲线。采用GEPIA2进行泛癌分析。采用ESTIMATE包进行微环境评分分析。结果·481例DLBCL患者样本中,481例均有RNA-seq的表达量数据,421例有临床分期,335例有国际预后指数(international prognostic index,IPI)评分,234例有生存数据。分类得出ABC亚型232例(48.2%)、GCB亚型173例(36.0%)、未分类76例(15.8%),与数据库声明的比例相符,经富集分析验证符合ABC/GCB表达谱特征。SOX9低表达量组与SOX9高表达量组相比,总生存期更短,预后分数更差。泛癌分析示该现象亦可见于其他类型肿瘤。差异分析显示,在GCB亚型中,与SOX9高表达量组相比,SOX9低表达量组中有上调基因156个、下调基因1 826个。对于细胞代谢水平的变化,下调基因富集于糖酵解。结论·在ABC-DLBCL中,SOX9基因通过调控代谢重编程影响ABC-DLBCL的生物学特征。低表达SOX9的DLBCL,预示着肿瘤中糖酵解减少;其肿瘤基质细胞浸润程度更低,并且有着更差的预后。
关键词: 性别决定区Y框转录因子9; 弥漫性大B细胞淋巴瘤; 代谢重编程
张漪蓉 , 魏玮庆 , 马皎 , 张雪 . 靶向SOX9调控弥漫性大B细胞淋巴瘤代谢重编程的研究[J]. 上海交通大学学报(医学版), 2023 , 43(10) : 1236 -1244 . DOI: 10.3969/j.issn.1674-8115.2023.10.003
Objective ·To explore the role played by the differentially expressed SRY-box transcription factor 9 (SOX9) gene in diffuse large B cell lymphoma (DLBCL), particularly in the regulation of metabolic reprogramming in the germinal center B-cell (GCB) like subtype. Methods ·The clinical information and gene expression profile data of 481 DLBCL patients retrieved from the NCICCR-DLBCL database were included. Data analysis and visualisation were performed by using R language version 4.1.3. The classification was performed by using a cell of origin subtype (COO) classification algorithm based on RNA-seq sequencing of expression. ABC/GCB features were used to annotate gene sets, and the classification was verified by gene set enrichment analysis. The ABC and GCB subgroup was dichotomised based on the mean expression of SOX9. Differential analysis was performed by using the DEseq2 package. The relationship between SOX9 and ABC-DLBCL metabolism was analysed by using KEGG (Kyoto Encyclopedia of Genes and Genomes) with the Hallmark annotation set. The survival curves were plotted by using the Kaplan-Meier method. The pan-cancer analysis was performed by using GEPIA2. The microenvironmental scoring analysis was performed by the ESTIMATE package. Results ·Of the 481 DLBCL patient samples, all the patients had RNA-seq expression data, 421 had clinical staging, 335 had international prognostic index (IPI) scores and 234 had survival data. The classification yielded 232 (48.2%) ABC subtypes, 173 (36.0%) GCB subtypes and 76 (15.8%) unclassified, consistent with the proportions declared in the database, and the enrichment analysis was verified to be consistent with the ABC/GCB expression profile. Compared to the high SOX9 expression group, the overall survival was shorter in the low SOX9 expression group and the prognostic score was worse. The pan-cancer analysis showed that this phenomenon was also seen in other tumor types. The differential analysis showed that there were 156 upregulated genes and 1 826 downregulated genes in the GCB subtype in the low SOX9 expression group, compared to the high SOX9 expression group. For metabolic processes, down-regulated genes were enriched in glycolysis. Conclusion ·In the ABC subtype of DLBCL, the SOX9 gene affects the biological features of ABC-DLBCL by regulating metabolic reprogramming, and low expression of SOX9 in DLBCL, possibly caused by high methylation, predicts decreased glycolysis in tumors. The proportion of tumor stromal cells decreases, showing a worse prognosis.
1 | ROSENWALD A, WRIGHT G, CHAN W C, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346(25): 1937-1947. |
2 | BEA S. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction[J]. Blood, 2005, 106(9): 3183-3190. |
3 | PAVLOVA N N, ZHU J J, THOMPSON C B. The hallmarks of cancer metabolism: still emerging[J]. Cell Metab, 2022, 34(3): 355-377. |
4 | HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. |
5 | CONDELLI V, CRISPO F, PIETRAFESA M, et al. HSP90 molecular chaperones, metabolic rewiring, and epigenetics: impact on tumor progression and perspective for anticancer therapy[J]. Cells, 2019, 8(6): 532. |
6 | SUN N Y, YANG M H. Metabolic reprogramming and epithelial-mesenchymal plasticity: opportunities and challenges for cancer therapy[J]. Front Oncol, 2020, 10: 792. |
7 | YIN G, LIANG Y, WANG Y, et al. mTOR complex 1 signalling regulates the balance between lipid synthesis and oxidation in hypoxia lymphocytes[J]. Biosci Rep, 2017, 37(1): BSR20160479. |
8 | KIRSCH B J, CHANG S J, BETENBAUGH M J, et al. Non-Hodgkin lymphoma metabolism[M]. Cham: Springer International Publishing, 2018. |
9 | PANDA M, TRIPATHI S K, BISWAL B K. SOX9: an emerging driving factor from cancer progression to drug resistance[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188517. |
10 | ENJUANES A, FERNàNDEZ V, HERNáNDEZ L, et al. Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma[J]. PLoS One, 2011, 6(5): e19736. |
11 | BENNETT L B, SCHNABEL J L, KELCHEN J M, et al. DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma[J]. Genes Chromosom Cancer, 2009, 48(9): 828-841. |
12 | CHENG P F, SHAKHOVA O, WIDMER D S, et al. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma[J]. Genome Biol, 2015, 16(1): 42. |
13 | PASSERON T, VALENCIA J C, NAMIKI T, et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid[J]. J Clin Invest, 2009, 119(4): 954-963. |
14 | PRéVOSTEL C, RAMMAH-BOUAZZA C, TRAUCHESSEC H, et al. SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/?-catenin signaling[J]. Oncotarget, 2016, 7(50): 82228-82243. |
15 | SLATTERY M L, HERRICK J S, MULLANY L E, et al. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer[J]. Genes Chromosom Cancer, 2017, 56(11): 769-787. |
16 | SCHMITZ R, WRIGHT G W, HUANG D W, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma[J]. N Engl J Med, 2018, 378(15): 1396-1407. |
17 | LEICH E, SALAVERRIA I, BEA S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations[J]. Blood, 2009, 114(4): 826-834. |
18 | SOTIRIOU C, WIRAPATI P, LOI S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis[J]. J Natl Cancer Inst, 2006, 98(4): 262-272. |
19 | REDDY A, ZHANG J, DAVIS N S, et al. Genetic and functional drivers of diffuse large B cell lymphoma[J]. Cell, 2017, 171(2): 481-494.e15. |
20 | SHAFFER A L, WRIGHT G, YANG L M, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology[J]. Immunol Rev, 2006, 210: 67-85. |
21 | SUBRAMANIAN A, TAMAYO P, MOOTHA V K, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci USA, 2005, 102(43): 15545-15550. |
22 | YOSHIHARA K, SHAHMORADGOLI M, MARTíNEZ E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. Nat Commun, 2013, 4: 2612. |
23 | JIANG Y W, HATZI K, ELEMENTO O, et al. Enhancer profiling reveals SOX9 as a novel transcription regulator of B cell activation and DLBCL transformation[J]. Blood, 2012, 120(21): 527. |
24 | SHEN Y J, ZHOU J Q, NIE K, et al. Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas[J]. Blood, 2022, 139(1): 73-86. |
25 | GOOPTU M, WHITAKER-MENEZES D, SPRANDIO J, et al. Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma[J]. Semin Oncol, 2017, 44(3): 204-217. |
26 | LAM L T, WRIGHT G, DAVIS R E, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma[J]. Blood, 2008, 111(7): 3701-3713. |
27 | JIANG Y W, HATZI K, SHAKNOVICH R. Mechanisms of epigenetic deregulation in lymphoid neoplasms[J]. Blood, 2013, 121(21): 4271-4279. |
/
〈 |
|
〉 |